Fig. 1: FGFR2 is upregulated in GC and serves as a poor prognostic biomarker. | Oncogene

Fig. 1: FGFR2 is upregulated in GC and serves as a poor prognostic biomarker.

From: FGF18–FGFR2 signaling triggers the activation of c-Jun–YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential

Fig. 1

a Genetic alterations (gene amplification, deep deletion, or somatic mutation) or mRNA upregulation of the main FGFR members in primary samples from the TCGA-GC cohort (n = 104, total alteration rate: 36%). b Correlation analysis of FGFR2 copy number changes and its mRNA expression in TCGA-GC samples (n = 258, **p < 0.001). c Upregulated FGFR2 mRNA expression correlates with shorter overall and first progression survival in multiple GSE cohorts (GSE14210, GSE15459, GSE22377, GSE29272, GSE51105, and GSE62254) (p < 0.001; HR, hazard ratio). d CISH analysis of FGFR2 (green) for DNA aberration detection in primary GC samples (Hong Kong cohort, n = 264; scale bar, 20 μm). Cases with copy number gain and cases with gene amplification count for 6% and 7%, respectively. e Representative images of IHC staining of FGFR2 in GC tissue microarray (TMA). FGFR2 predominantly localized in the cytoplasmic and membrane of diffuse/intestinal type cancer cells (scale bar, 100 μm for lower resolution and 20 μm for higher resolution). Overexpressed FGFR2 is associated with poor disease-specific survival in primary GCs (Hong Kong cohort, n = 264; p = 0.025; HR = 1.48). f The mRNA expression of FGFR1-4 in 11 GC cell lines. g FGFR2 protein expression in GC cell lines and normal gastric epithelial samples.

Back to article page